Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 12.01
- Piotroski Score 1.00
- Grade Buy
- Symbol (ANIX)
- Company Anixa Biosciences, Inc.
- Price $3.15
- Changes Percentage (-1.25%)
- Change -$0.04
- Day Low $3.03
- Day High $3.21
- Year High $5.13
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/01/2025
- Fiscal Year End N/A
- Average Stock Price Target $7.50
- High Stock Price Target $8.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.37
- Trailing P/E Ratio -6.89
- Forward P/E Ratio -6.89
- P/E Growth -6.89
- Net Income $-9,811,000
Income Statement
Quarterly
Annual
Latest News of ANIX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Breakeven Is Near for Botanix Pharmaceuticals Limited (ASX:BOT)
Botanix Pharmaceuticals Limited is analyzed for potential profitability, with analysts predicting breakeven in 2025. Despite high growth expectations and irregular cash flows typical in the pharmaceut...
By Yahoo! Finance | 3 days ago -
Nutanix, Inc. (NASDAQ:NTNX) is favoured by institutional owners who hold 79% of the company
Institutional ownership of Nutanix (NASDAQ:NTNX) stands at 79%, which can significantly impact stock price. Top shareholders include FMR LLC, The Vanguard Group, and Bain Capital, with no single entit...
By Yahoo! Finance | 1 week ago -
Nutanix, Inc. (NTNX): An Under The Radar AI Stock You Should Pay Attention To
The article highlights the impact of AI in under-the-radar industries like utilities, mining, and media, emphasizing efficiency and innovation. It discusses the potential and applications of AI tools ...
By Yahoo! Finance | 3 weeks ago